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Essentials
• Between-lab variations of cut-off values in lupus antico-
agulant detection are unknown.
• Cut-off values were calculated in 11 labs each testing
plasma from 120 donors with 3 platforms.
• Major variation was observed even within the same
platform.
• Cut-off values determined in different labs are not inter-
changeable.
Summary. Background: Cut-off values for interpretation
of lupus anticoagulant (LA) detection are poorly investi-
gated. Aims: (i) To assess whether results from healthy
donors were normally distributed and (ii) the between-
laboratories differences in cut-off values for screening,
mixing and LA confirmation when calculated as 99th or
95th centiles, and (iii) to assess their impact on the
detection rate for LA. Methods: Each of 11 laboratories
using one of the three widely used commercial platforms
for LA detection was asked to collect plasmas from 120
healthy donors and to perform screening, mixing and
LA confirmation with two methods (activated partial
thromboplastin time [APTT] and dilute Russell viper
venom [dRVV]). A common set of LA-positive or LA-
negative freeze-dried plasmas was used to assess the LA
detection rate. Results were centralized (Milano) for sta-
tistical analysis. Results and conclusions: (i) Clotting
times or ratios for healthy subjects were not normally
distributed in the majority of cases. The take-home mes-
sage is that cut-off values should be determined prefer-
ably by the non-parametric method based on centiles.
(ii) There were relatively large inter-laboratory cut-off
variations even within the same platform and the vari-
ability was marginally attenuated when results were
expressed as ratios (test-to-normal pooled plasma). The
take-home message is that cut-off values should be
determined locally. (iii) There were differences between
cut-off values calculated as 99th or 95th centiles that
translate into a different LA detection rate (the lower
the centile the greater the detection rate). The take-home
message is that cut-off values determined as the 95th
centile allow a better LA detection rate.
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Introduction
Lupus anticoagulants (LAs) are a heterogeneous family
of immunoglobulins that upon binding to complexes of
proteins and negatively charged phospholipids prolong
phospholipid-dependent coagulation tests in vitro, but
are responsible for venous/arterial thromboembolism and
pregnancy complications [1]. Positivity for LA is consid-
ered to be one of the laboratory criteria to define the
antiphospholipid syndrome [2] and its persistent positiv-
ity in combination with previous thrombotic events qual-
ifies the patient for long-term anticoagulation [1]. Hence,
the laboratory detection of LA is of paramount impor-
tance. Unfortunately, no specific test for LA exists and
its detection rests on phospholipid-dependent coagulation
tests combined with a set of diagnostic criteria developed
and issued by the Scientific and Standardization Com-
mittee (SSC), Subcommittee for Lupus Anticoagulant/
Phospholipid-Dependent Antibodies of the International
Society on Thrombosis and Haemostasis (ISTH). They
include the following: (a) evidence that one (or more)
phospholipid-dependent coagulation test is prolonged
beyond the upper limit of the normal range; (b) evidence
that the prolongation does not revert to normal upon
mixing equal portions of patient and normal plasma;
and (c) evidence that the circulating anticoagulant is
directed against negatively charged phospholipids, com-
plexed with proteins, and not directed against specific
coagulation factors. Criteria a, b and c are called screen-
ing, mixing and confirmation, respectively [3]. The LA
ISTH guidelines recommend two types of tests for LA
detection, including an activated partial thromboplastin
time (APTT)-derived and a dilute Russell viper venom
(dRVV)-derived test. Analyses with these two tests
include screening, mixing and confirmation procedures.
Results obtained with the above procedures should be
interpreted by comparing the patients’ values with
specific cut-off values determined for each test and
procedure.
There are no studies evaluating the variation in the LA
cut-off values as determined in different laboratories with
different platforms or the effect that the statistical analy-
sis might have on interpretation of results. All the above
issues prompted us to organize and carry out an interna-
tional multicenter multiplatform study with the aim of
assessing the variations in cut-off values specific for com-
binations of tests and coagulometers (here called plat-
forms), run in different laboratories, when testing
relatively large numbers of plasmas from healthy donors.
Results have been compared in order to assess between-
laboratory differences while using the same platform but
different sets of plasmas from healthy donors. Other aims
of the study were to assess whether results from healthy
donors are ‘normally’ distributed and the extent of differ-
ences in the cut-off values determined by different meth-
ods of calculation. A common set of LA-positive plasmas
has been used to assess the impact that different cut-off
values can have on the LA detection rate.
Material and methods
Design of the study
Manufacturers of three widely used platforms for LA
detection were asked to support the study. Instrumenta-
tion Laboratory, Diagnostica Stago (Asnieres, France)
and Siemens Healthcare Diagnostics (Marburg, Germany)
were contacted and agreed to participate. With their help,
we selected five (or more) laboratories within each plat-
form and they were asked to join the study by collecting
120 plasma samples from individual healthy donors. Par-
ticipants were provided with a protocol detailing how
blood donors should be selected, handling of blood,
plasma preparation and storage, and testing (see below).
The reagents needed to run the tests in each laboratory
were provided by the relevant manufacturers. At the end
of the study, the results were entered into a (provided)
data collection form and sent to the organizing laboratory
(Milano) for centralized statistical analysis.
Selection of healthy donors
Participants were asked to select 120 male and female
(60 : 60) healthy donors who ranged in age from 18 to
70 years, were in good health and were free from diseases
or drugs known to affect coagulation. ISTH guidelines
for LA detection suggest selecting donors who are less
than 50 years of age [3]. We elected to expand the age
range in order to increase the likelihood of individual cen-
ters accessing the requisite number of donors. Blood
donors were acceptable provided that blood samples were
collected by a separate venipuncture before or a long time
after blood donation. Participants were free to collect the
blood samples needed to complete the study on different
days according to local availability.
Blood collection and plasma preparation
Participants were asked to collect venous blood into vac-
uum tubes containing 1/10 trisodium citrate 109 mM and
to prepare plasma from double centrifugation as recom-
mended by the ISTH guidelines to obtain platelet-poor
plasma [3]. Plasmas were to be stored frozen at 70 °C
until testing. Samples collected before planning this study
were permitted if their preparation fulfilled the recom-
mendations in the ISTH guidelines [3] and they had been
stored at 70 °C for no longer than 12 months.
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Pooled normal plasma
Participants were advised to prepare the pooled normal
plasma (PNP) locally by collecting blood samples from
30 healthy donors (15 : 15; male : female) into vacuum
tubes containing 1/10 volume trisodium citrate 109 mM.
Blood was centrifuged as for samples from blood donors
used for the study. Equal amounts of the individual plas-
mas had to be pooled in a plastic container and after
mixing the bulk of PNP had to be divided into small ali-
quots (~1.0 mL) in plastic capped tubes that had to be
stored frozen at 70 °C and tested in parallel with the
samples from blood donors. The same PNP had to be
used to perform the mixing study. In case of unavailabil-
ity of local PNP a lyophilized commercial preparation
that fulfilled the SSC requirements for LA testing could
be used.
Freeze-dried plasmas
Suitable numbers of vials of the 1st International Refer-
ence Panel for Lupus Anticoagulant, 13/172, consisting of
freeze-dried plasma that was negative (plasma A) or posi-
tive for LA (B, weak; C, strong) were provided by NIBSC
(Potters Bar, Hertfordshire, UK) and were sent to each
participating laboratory as coded unknown plasmas in
order to assess them for LA detection rate with different
methods of calculating cut-off values. Information on
how to reconstitute the plasmas was provided. Partici-
pants were asked to test plasmas A, B, C and B diluted
1 : 2 with the local PNP, on three test occasions.
Testing
Participants were asked to complete the study by testing
the 120 samples from healthy donors and the NIBSC
unknown freeze-dried plasmas using an APTT-based test
and a dRVV-based test. Participants were free to split all
the measurements on different days according to the labo-
ratory workload. Single or duplicate measurements had
to be taken according to the local practice. Participants
were asked to run the following procedures.
Screening Testing was performed for the platelet-poor
plasma with the phospholipid-dependent screening
(APTT- and dRVV-based) tests according to the manu-
facturer’s specification.
Mixing Testing was performed upon mixtures of equal
portions of platelet-poor plasma from each donor and
local PNP. The mixture was tested without pre-incubation.
Confirmation Testing was performed for the (undiluted)
platelet-poor plasma with the confirmation tests of the
same reagent for screening tests with higher concentra-
tions of phospholipids as specified by the manufacturer.
Results (average values if duplicates) for the screening,
mixing and confirmatory procedures had to be entered
into the data collection form as clotting times (seconds),
together with the clotting time of the PNP run in parallel.
It should be noted that the methods provided by the three
manufacturers and used in this study, although sharing
the same principles (APTT-based or dRVV-based), are
substantially different in terms of reagent composition
and hence performance.
Data analysis
Results for the APTT-derived and dRVV-derived tests
obtained with screening, mixing and confirmation have
been analyzed to calculate cut-off values from data
obtained by each participant. Raw data used for the analy-
sis were clotting times for screening and mixing and percent-
age correction or Delta, calculated from results obtained
with confirmation procedures performed at low and high
phospholipid concentrations. Mixing has been assessed
according to the widely used method of Rosner [4] by means
of the index of circulating anticoagulants (ICA) as
%ICA ¼ ½ðCTmixture  CTPNPÞ=CTpatient  100
where CT stands for the clotting time. Confirmation has
been assessed as percentage correction (%correction)
according to [5]
%correction ¼ ½ðCTlowPL  CThighPLÞ=CTlowPL  100
or Delta according to
Delta ¼ CTlowPL  CThighPL
where PL stands for the phospholipid concentrations.
Cut-off values for the three procedures were also calcu-
lated by using ratios (patient-to-PNP) for clotting times.
Data were tested to assess for deviation from the normal
(Gaussian) distribution by means of the Kolmogorov–Smir-
nov test with P < 0.05. Cut-off values have been determined
by different methods of calculation for each participant,
method and procedure without exclusion of outliers. Cen-
tiles were calculated from the distribution of the data
according to the weighted average method. Results
obtained for the freeze-dried NIBSC LA plasmas were used
to calculate the LA detection rate achieved by the different
methods of calculating cut-off values. For the calculations
of detection rates, plasmas were considered LA positive
when the result for each procedure and method was greater
than the cut-off value determined in this study according to
each of the investigated methods of calculation. Analyses
were performed with the IBM SPSS Statistics version 23
Software (New York, NY, USA).
Results
Three groups, each composed of five participants, were
identified among those laboratories that used routinely
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one of the three commercial platforms (here called IL,
Siemens and Stago). All of them agreed to participate
and received the protocol. At the end of the study, results
were received from four, two and five participants in the
IL, Siemens and Stago groups, respectively. Eight partici-
pants were from Europe and there was one each from
India, North America and South America. The LA detec-
tion platforms used in the study are shown in Table 1.
One laboratory did not provide PNP results for the con-
firmation procedure; two reported duplicate rather than
triplicate measurements for the freeze-dried LA plasmas
and one did not perform confirmatory assays.
Deviation from the normal (Gaussian) distribution
The preliminary analysis showed that in many instances
(> 50%) there was a significant deviation (P < 0.05) from
the normal distribution (Table 2). In particular, deviations
were more often observed when results were expressed as
clotting times (average 60%) than as ratios (average
49%). Finally, deviations were more often observed for
the APTT-derived methods (average, 57%) than for
dRVV-derived (average, 51%) methods. Because of the
above deviations, it was decided to calculate cut-off val-
ues by means of non-parametric statistics and the 99th
and 95th centiles were chosen for further analysis.
Cut-off values
Cut-off values calculated for the three procedures (screen-
ing, mixing and confirmation) for all the laboratories,
platforms, tests (APTT-derived and dRVV-derived) and
results are shown in Figs 1 and 2. Table 3 shows the
median and range (minimum–maximum) of cut-off values
for each platform/test and method of calculation. As
expected, cut-off values were shorter when calculated as
the 95th vs. 99th centile. Overall, there was a relatively
large between-laboratory variability (even within the same
platform) with no major improvement when results were
expressed as a ratio (patient-to-PNP) for the APTT-
derived or dRVV-derived methods.
LA detection rate
NIBSC freeze-dried plasmas have been used to assess the
LA detection rate obtained for each laboratory with each
platform for screening, mixing and confirming. Results
are shown in Tables 4 and 5.
APTT derived Overall, detection rates for screening,
mixing or confirming were excellent for plasma A (nega-
tive) regardless of the method of calculating cut-off val-
ues, good for plasma C (strongly positive), acceptable for
B (weakly positive), but low for plasma B diluted 1 : 2 in
PNP (Table 4). For plasma B (undiluted or diluted), the
detection rate was better when cut-offs were calculated as T
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95th centiles rather than as 99th centiles. Overall, detec-
tion rates for confirming were similar when cut-off values
were calculated as Delta or as % correction. There were
no major differences between the detection rates calcu-
lated from clotting times as compared with those calcu-
lated from ratios.
Table 2 Details of the analysis to assess whether results from individual laboratories were ‘normally’ distributed. Number (%) represents the
proportion of deviation from ‘normality’ (P < 0.05) for each method and expression of results
Test
Kolmogorov-Smirnov test
Clotting time (seconds) Ratio (patient plasma to PNP)
IL Siemens Stago All IL Siemens Stago All
APTT - screening 2/4 1/2 3/5 6/11 1/4 1/2 3/5 5/11
APTT - mixing (ICA%) 2/4 1/2 3/5 6/11 2/4 1/2 3/5 6/11
APTT - confirm (% correction) 2/4 1/2 4/4 7/10 1/3 0/2 3/4 4/9
APTT - confirm (Delta) 2/4 2/2 4/4 8/10 1/3 1/2 3/4 5/9
dRVV - screening 2/4 1/2 5/5 8/11 2/4 2/2 4/5 8/11
dRVV - mixing (ICA%) 0/4 0/2 3/5 3/11 0/4 0/2 0/5 0/11
dRVV - confirm (% correction) 1/4 1/2 3/4 5/10 0/3 1/2 3/4 4/9
dRVV - confirm (Delta) 2/4 1/2 4/4 7/10 2/3 1/2 4/4 7/9
Overall 13/32 (40) 8/16 (50) 29/36 (81) 50/84 (60) 9/28 (32) 7/16 (44) 23/36 (64) 39/80 (49)
APTT, activated partial thromboplastin time; ICA, index of circulating anticoagulant; IL, Instrumentation Laboratory; dRVV, dilute Russell
viper venom test; PNP, pooled normal plasma.
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Fig. 1. APTT-derived cut-off values determined in different laboratories using three commercial platforms for LA detection for screening, mix-
ing and confirmation procedures. Cut-off values have been determined according to clotting times (upper panels) or ratio of patient plasma to
PNP (lower panels) as the 99th (closed symbols) or 95th (open symbols) centiles of distribution of results for healthy donors. APTT, activated
partial thromboplastin time; ICA, index of circulating anticoagulant; LA, lupus anticoagulant; IL, Instrumentation Laboratory; PNP, pooled
normal plasma; ST, Stago; SM, Siemens; ICA, index of circulating anticoagulant calculated as ICA = [(CTmixture – CTPNP)/CTpatient] 9 100;
% correction calculated as % correction = [(CTlowPL – CThighPL)/CTlowPL] 9 100. Delta calculated as Delta = CTlowPL – CThighPL.
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dRVV derived Overall, detection rates for screening,
mixing or confirming were excellent for plasma A (nega-
tive) and plasma C (strongly positive) regardless of the
method of calculating cut-off values, acceptable for
plasma B (weakly positive), but very low for plasma B
diluted 1 : 2 in PNP (Table 5). For plasma B (undiluted
or diluted), the detection rate was better when cut-off val-
ues were calculated as 95th centiles rather than as 99th
centiles. Overall, detection rates for confirming were simi-
lar when cut-off values were calculated as % correction
or as Delta. There were no major differences between the
detection rates calculated from clotting times as compared
with those calculated from ratios.
Discussion
Surveys performed over the years [6–13] have shown the
variable performance of clinical laboratories with respect
to sensitivity and specificity of LA tests. The rates of
false-positive and false-negative detections remain rela-
tively high. The former are of particular concern because
they qualify the patients for long-term and unnecessary
oral anticoagulant treatment [1]. Although some of the
reasons for the poor performances have been elucidated
[14], some others, such as the effect of cut-off values,
although investigated in a multicenter study with a single
platform [15], are still poorly understood. The ISTH
guidelines for LA detection recommend testing plasmas
from 40 or more healthy donors and taking the cut-off as
the value corresponding to the 99th centile of their distri-
bution for the screening and mixing procedures and as
the mean percentage correction (low vs. high phospho-
lipid concentration) for the confirmation procedure [3].
However, for most laboratories it is difficult to follow
these recommendations, as plasmas from healthy donors
are not readily available. Commercial frozen normal plas-
mas, if available, are difficult to access because of their
cost. Furthermore, taking the 99th centile of the distribu-
tion of results from healthy donors as the cut-off value
may give rise to bias when plasmas are less than 100.
Finally, most laboratory operators are much more famil-
iar with the cut-off values determined as the interval
defined by the parametric methods (i.e. mean + SD),
which was, however, not recommended in the ISTH
guidelines as it was felt that the data were not normally
distributed. Last but not least, most manufacturers
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Fig. 2. dRVV-derived cut-off values determined in different laboratories using three commercial platforms for LA detection for screening, mix-
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provide in the package insert for their products, indica-
tions on cut-off values to be used in each laboratory to
interpret results obtained with the same combination of
reagent and coagulometer (platform). The validity of this
procedure has, however, not been thoroughly investigated
to see whether small variations in the application of test-
ing in different laboratories may introduce local bias in
the determination of cut-off as well as patient values and
hence in the interpretation of results.
The present study aimed to answer some of these ques-
tions. We identified three widely used commercial plat-
forms for LA detection and selected five clinical
laboratories across the world using each of the three plat-
forms. Each laboratory was asked to include in the study
at least 120 healthy donors and a common set of freeze-
dried plasmas negative or positive for LA that were to be
tested along with the donors’ plasmas. The collaborative
study gave the opportunity to collect and analyze huge
numbers of data (i.e. > 20 000) that are not completely
analyzed here and will form the basis of additional
reports.
Interestingly, there were differences in dealing with the
LA detection policy between different platforms. All
included in their protocol APTT-derived and dRVV-
derived tests as recommended by the ISTH guidelines [3].
However, three platforms used integrated tests (i.e. dual
tests at low and high phospholipid concentrations) for the
dRVV-derived tests. For the APTT-derived test, the
approach was different. Laboratories with the Siemens
platform used a brand of APTT for screening/mixing and
a different brand of APTT for confirmation. Laboratories
with the Instrumentation Laboratory (IL) platform used
an integrated test and laboratories with the Stago plat-
form used a brand of APTT for screening/mixing and a
Table 3 Median (minimum and maximum) of cut-off values obtained by participants according to different platforms and models of calcula-
tion (99th or 95th centile, seconds or ratio [patient-to-PNP])
Clotting time (seconds) Ratio (patient plasma to PNP)
IL SM ST IL SM ST
99th 95th 99th 95th 99th 95th 99th 95th 99th 95th 99th 95th
APTTscreen
Median 45.9 40.4 36.8 34.0 46.6 43.3 1.38 1.24 1.30 1.21 1.30 1.23
Min 39.8 37.2 36.5 33.5 43.8 40.1 1.21 1.15 1.28 1.17 1.27 1.19
Max 50.3 47.2 37.1 34.5 48.5 45.5 1.43 1.35 1.33 1.25 1.42 1.29
APTTmix*
Median 11.9 8.2 22.9 13.7 10.7 6.4 11.17 8.93 22.89 13.42 10.85 7.66
Min 7.5 5.9 11.6 6.6 8.5 5.6 7.67 6.12 11.61 5.98 8.75 5.58
Max 27.2 12.4 34.2 20.8 11.6 10.0 24.73 11.17 34.16 20.86 12.71 10.29
APTTcorr†
Median 21.1 13.7 16.3 10.6 10.8 5.6 21.2 11.8 19.7 14.5 12.0 6.6
Min 13.9 9.3 15.6 9.7 7.8 3.4 13.1 9.4 13.9 10.0 7.4 5.3
Max 29.3 20.4 17.0 11.5 15.5 9.3 22.6 14.6 25.4 19.1 15.6 7.6
APTTdelta‡
Median 9.0 5.2 5.4 3.2 6.2 2.7 0.23 0.14 0.23 0.15 0.13 0.07
Min 4.9 3.2 5.0 2.9 3.6 1.9 0.14 0.10 0.15 0.10 0.09 0.06
Max 11.5 8.8 5.8 3.4 6.9 4.8 0.29 0.18 0.31 0.20 0.19 0.08
dRVVscreen
Median 42.4 38.7 45.3 42.3 55.7 50.1 1.33 1.21 1.29 1.21 1.37 1.23
Min 41.1 34.9 44.0 41.9 49.8 43.0 1.27 1.10 1.19 1.17 1.29 1.14
Max 49.4 39.7 46.6 42.7 69.8 54.7 1.56 1.22 1.39 1.26 1.71 1.50
dRVVmix*
Median 11.6 7.0 16.8 9.3 12.1 8.3 12.1 7.3 17.0 10.0 13.1 6.8
Min 9.3 4.3 14.4 9.3 1.7 0.2 10.6 4.3 14.5 9.6 2.0 0.4
Max 24.5 17.7 19.3 9.3 15.4 10.4 23.6 18.2 19.4 10.3 15.5 11.2
dRVVcorr†
Median 30.8 21.5 27.6 18.0 31.5 18.6 21.2 9.6 23.7 14.9 29.6 14.4
Min 28.3 20.3 25.1 16.7 25.1 16.1 19.4 8.9 19.9 13.2 23.0 12.9
Max 33.3 29.3 30.1 19.2 36.9 25.2 21.2 13.3 27.4 16.6 36.3 23.0
dRVVdelta‡
Median 12.5 7.8 12.5 7.2 16.0 8.6 0.26 0.11 0.31 0.17 0.40 0.18
Min 11.2 6.9 10.9 6.3 13.9 6.8 0.26 0.10 0.24 0.16 0.30 0.14
Max 16.5 11.6 14.0 8.1 26.0 13.7 0.33 0.16 0.38 0.19 0.61 0.33
APTT, activated partial thromboplastin time; dRVV, dilute Russell viper venom tests; ICA, index of circulating anticoagulant; IL, Instrumen-
tation Laboratory; SM, Siemens; ST, Stago; CT, clotting time; PNP, pooled normal plasma; PL, phospholipids. *Calculated as %
ICA = [(CTmixture – CTPNP)/CTpatient] 9 100. †% correction = [(CTlowPL – CThighPL)/CTlowPL] 9 100. ‡Delta = CTlowPL – CThighPL.
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different brand of APTT with dual tests without and with
hexagonal phospholipids for confirmation. From the scru-
tiny of results, the following conclusions on cut-off values
and LA detection rates can be drawn.
Cut-off values
As expected, there were differences in the cut-off values
for the different platforms when results were expressed as
clotting times and these differences were not attenuated
when results were expressed as a ratio (see Figs 1 and 2,
Table 3). It is of more interest to note that in general
there were differences in the cut-off values determined
from results stemming from participants using the same
platform. This is (apparently) an unexpected finding, but
the most likely explanation rests on the between-labora-
tory differences of the selected population of donors com-
bined with small differences brought about by the
different lots of reagents employed in different laborato-
ries, together with small between-laboratory differences in
the application of the same platform. In contrast to a pre-
vious paper that reported cut-off values determined in five
laboratories and for a single platform using the same lot
of reagents [15], in the present study the between-labora-
tory differences were only marginally attenuated when
results were expressed as a ratio. The reason probably
rests with the variability of PNP prepared in different lab-
oratories. Perhaps, a common international standard
PNP is needed to harmonize results between laboratories.
However, this notwithstanding, clinical laboratories
should be encouraged to express their results as ratios, as
this minimizes the day-to-day variability. Another reason
for the between-laboratory variation in cut-off observed
in the study when using the same platform may be the
different lots of reagents or blood collecting systems used
in different laboratories with the same platform. Indeed,
two laboratories that used the same platform and shared
the same lot of reagents obtained similar cut-off values
(not shown). Overall, the relatively high inter-laboratory
variability in the cut-off values even within the same plat-
form observed in this study should be indicative of the
notion [16], until now not directly documented in a large
collaborative study involving many laboratories and three
widely used commercial platforms, that cut-off values
should be determined locally and that the values reported
in the reagent package insert must be taken only as pre-
liminary information.
The study also investigated whether results from
healthy donors are or are not normally distributed. On
average, more than half of the datasets were not normally
distributed and there were differences between methods
and platforms. Hence, the practice of using the
Table 4 APTT-derived LA detection rate according to different cut-off values. Numbers represent the percentage of positive detection obtained
by participants [(n. of positive LA/n. of observations) 9 100] while testing the common LA-negative (plasma A), LA-strongly-positive (plasma
C), LA-weakly-positive (plasma B) and plasma B diluted 1:2 in PNP
Plasmas
Clotting time (seconds) Ratio (patient plasma to PNP)
IL SM ST TOT IL SM ST TOT
99th 95th 99th 95th 99th 95th 99th 95th 99th 95th 99th 95th 99th 95th 99th 95th
Screening APTT-derived
A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
B 100 100 0 50 100 100 81 91 100 100 0 33 100 100 81 88
C 100 100 50 50 100 100 91 91 100 100 50 50 100 100 91 91
B diluted1:2 57 86 0 0 43 100 37 74 71 100 0 0 43 93 41 74
Mixing APTT-derived*
A 0 0 0 0 0 14 0 6 0 0 0 0 0 0 0 0
B 83 100 0 60 100 100 77 94 100 100 0 40 100 100 84 90
C 100 100 60 60 100 100 94 94 100 100 40 60 100 100 90 94
B diluted1:2 71 100 0 0 79 100 62 81 71 100 0 0 71 100 58 81
Confirm APTT-derived as % correction†
A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
B 92 100 0 60 60 90 63 89 100 100 0 40 60 80 65 81
C 92 100 60 60 78 100 81 92 100 100 60 60 78 89 84 88
B diluted1:2 57 100 0 20 67 89 48 76 50 100 0 20 67 89 45 75
Confirm APTT as Delta‡
A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
B 100 100 0 60 80 90 74 89 100 100 20 60 80 90 77 89
C 100 100 60 60 89 100 88 92 100 100 60 60 78 89 84 88
B diluted1:2 57 100 0 40 67 89 48 81 50 100 0 20 67 89 45 75
APTT, activated partial thromboplastin time; LA, lupus anticoagulant; dRVV, dilute Russell viper venom test; IL, Instrumentation Labora-
tory; SM, Siemens; ST, Stago; TOT, total; ICA, index of circulating anticoagulant; CT, clotting time; PNP, pooled normal plasma; PL, phos-
pholipids. *Calculated as ICA = [(CTmixture – CTPNP)/CTpatient] 9 100. †% correction = [(CTlowPL – CThighPL)/CTlowPL] 9 100.
‡Delta = CTlowPL – CThighPL.
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parametric method for calculating cut-off, based on the
mean + SD, is questionable and the more robust non-
parametric calculation based on centiles should be imple-
mented. As expected, the cut-off values were smaller
when calculated as 95th rather than 99th centiles. It
should, however, be pointed out that the choice between
the two models of calculation should be based on the LA
detection rate determined with truly positive or negative
plasma rather than on statistical considerations. This is
especially important if one considers that persistently pos-
itive LA combined with previous thrombosis qualifies
patients for long-term anticoagulation [1].
LA detection rate
Although defining truly positive or negative LA plasmas
is difficult because of the lack of specific tests, we
attempted to investigate the LA detection rate using a
common set of previously validated LA plasmas that had
been tested by the participants along with the plasmas
from donors. From scrutiny of the results, the following
considerations can be derived.
LA-negative plasma It is reassuring that no false-posi-
tive LAs were found by participants when testing plasma
A (LA-negative), both for the APTT-derived and dRVV-
derived tests (screening, mixing and confirming), whatever
the methods for calculating cut-off or expressing results,
except for the screening dRVV Siemens platform when
cut-off was calculated as the 95th centile with results
expressed as clotting times (see Tables 4 and 5). The
inherent limitation of the above conclusions rests on the
fact that plasma A was negative for LA but had normal
clotting time. A negative-LA plasma with abnormal
clotting time would have been needed to draw definite
conclusions.
LA-strongly-positive plasma Overall, the LA detection
rate obtained by participants when using the APTT-
derived test was high for plasma C (strongly positive)
(range of values, 81–94%) (see Table 4). The detection
rate was slightly better when using more stringent cut-off
values (95th centiles) regardless of the expression of
results. For the dRVV-derived tests, the detection rates
were higher than those observed for the APTT-derived
tests (range of values, 90–100%), with slightly better
detection rates when using more stringent cut-off values
(95th centiles) regardless of the expression of results (see
Table 5).
LA-weakly-positive plasmas For plasma B (weakly posi-
tive), detection rates for the APTT-derived methods were
(as expected) smaller than those observed for the strongly
positive plasma (range of values, 63–94%), with a better
Table 5 dRVVT-derived LA detection rate according to different cut-off values. Numbers represent the percentage positive detection
obtained by participants [(n. of positive LA/n. of observations) 9 100] while testing the common LA-negative (plasma A), LA-strongly positive
(plasma C), LA-weakly positive (plasma B) and plasma B diluted 1:2 in a PNP (see also legend to Table 4)
Plasmas
Clotting time (seconds) Ratio (patient plasma to PNP)
IL SM ST TOT IL SM ST TOT
99th 95th 99th 95th 99th 95th 99th 95th 99th 95th 99th 95th 99th 95th 99th 95th
Screening dRVV-derived
A 0 0 0 17 0 0 0 3 0 0 0 17 0 0 0 3
B 67 100 100 100 57 100 69 100 67 100 100 100 57 93 69 97
C 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
B diluted1:2 0 29 0 33 0 31 0 31 0 14 17 17 0 23 4 19
Mixing dRVV-derived*
A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
B 67 75 0 100 100 100 69 91 67 75 0 83 79 100 59 88
C 75 100 100 100 100 100 91 100 92 100 100 100 100 100 97 100
B diluted1:2 0 14 0 0 0 33 0 20 0 0 0 0 8 17 4 8
Confirm dRVV-derived as % correction†
A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
B 58 92 100 100 29 100 53 97 46 100 100 100 0 79 36 90
C 92 100 100 100 100 100 97 100 100 100 100 100 79 79 90 90
B diluted1:2 0 43 0 100 0 31 0 50 0 43 17 83 0 23 4 44
Confirm dRVV as Delta‡
A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
B 75 92 100 100 43 100 66 97 55 100 100 100 14 79 45 90
C 92 100 100 100 100 100 97 100 100 100 100 100 79 79 90 90
B diluted1:2 0 43 0 100 0 46 0 58 0 43 17 83 0 23 4 44
LA, lupus anticoagulant; dRVV, dilute Russell viper venom test; ICA, index of circulating anticoagulant; IL, Instrumentation Laboratory; SM,
Siemens; ST, Stago; TOT, total; CT, clotting time; PNP, pooled normal plasma; PL, phospholipids. *Calculated as ICA = [(CTmixture –
CTPNP)/CTpatient] 9 100. †% correction = [(CTlowPL – CThighPL)/CTlowPL] 9 100. ‡Delta = CTlowPL – CThighPL.
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detection rate when using more stringent cut-off values
(95th centiles) regardless of the expression of results.
Finally, when plasma B (weakly positive) was diluted
1 : 2 in PNP, the LA potency for the APTT-derived test
became very weak and the detection rate considerably
lower (range of values, 37–81%), with a better detection
rate when using more stringent cut-off values (95th cen-
tiles) regardless of the expression of results (see Table 4).
For the dRVV-derived tests, detection rates for plasma B
were similar to those observed for the APTT-derived tests
(range of values, 53–100%). It is of interest that detection
rates for the diluted plasma B were smaller for the
dRVV-derived (range of value, 0–58%) than those
observed for the APTT-derived tests (37–81%) (see
Tables 4 and 5). However, no definitive conclusions can
be drawn on the performance of the APTT-derived vs.
the dRVV-derived tests in detecting LA, as the results
pertain to the specific set of LA plasmas used in this
study, which are not necessarily representative of the
whole population of patients with LA. In addition, none
of the plasmas in the panel had abnormal prolonged clot-
ting time because of the presence of coagulation factor
deficiencies or presence of an inhibitor other than LA.
There were differences in the LA detection rate according
to the method of calculating cut-off: those based on 99th
centiles were smaller than those based on 95th centiles
(see Table 3). These findings may be of considerable prac-
tical interest. Owing to the lack of standardization of LA
reporting [17], the potency of LA in individual patients
cannot be accurately determined. Therefore, although sur-
mised [18], it is not yet known with certainty if weak LA
positivity is as clinically relevant as strong LA positivity.
It can be argued that if the goal of the laboratory is to
pick up not only the strongly positive but also the weakly
positive patients, more stringent cut-off values based on
the 95th centiles should be selected. This choice would
carry the risk of increasing the numbers of false-positive
patients and should therefore be carefully considered.
Although we recognize that the presence of outliers
could overstate the estimated variability, in this prelimi-
nary evaluation, we elected to analyze all the results stem-
ming from the participants without detection (and
rejection) of outliers. Some guidance on the methods that
are useful for outlier detection when calculating cut-off
values for laboratory parameters of clinical interest has
been given previously [see 19 for more details]. However,
no clear recommendations on the best method to use, nor
evaluation of the impact that different methods may have
on interpretation of result, have been established. Fur-
thermore, owing to the complexity of the diagnostic pro-
cedures, the detection of outliers in the LA setting might
require strategies that are different from those used for
other parameters. Hence, we believe that further analyses
of the data collected in this collaborative study are appro-
priate to investigate the impact of different models of
outlier detection and these will form the basis of a specific
report that is in preparation.
In conclusion, the collaborative study involving 11 lab-
oratories collecting plasmas from hundreds of donors and
using the three widely used commercial platforms for LA
detection leads to the following considerations. (i) Clot-
ting times or ratios for healthy subjects were not normally
distributed in the majority of cases. The take-home mes-
sage is that cut-off values should be determined prefer-
ably by the non-parametric method based on centiles. (ii)
There are relatively large between-laboratory cut-off vari-
ations even within the same platform and the variability
is marginally attenuated when results are expressed as
ratios. The take-home message is that cut-off values
should be determined locally. (iii) There are major differ-
ences between cut-off values calculated as 99th or 95th
centiles that translate into a different LA detection rate
(the lower the centile the greater the detection rate). The
take-home message is that cut-off values determined as
the 95th centile allow a better LA detection rate.
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